Table 1. Baseline demographic and clinical characteristics of 51 recipients of HCTs.
| Characteristic | Total (n=51) | |
|---|---|---|
| Median age (range, yr) | 41 (20–64) | |
| Male | 32 (63) | |
| Underlying disease | ||
| Acute myeloid leukemia | 32 (63) | |
| Myelodysplastic syndrome | 8 (16) | |
| Aplastic anemia | 6 (12) | |
| Acute lymphocytic leukemia | 2 (4) | |
| Chronic myeloid leukemia | 1 (2) | |
| Non-Hodgkin's lymphoma | 1 (2) | |
| Hemophagocytic lymphohistiocytosis | 1 (2) | |
| Transplant type | ||
| Full allogeneic | 10 (20) | |
| Non-myeloablative allogeneic | 41 (80) | |
| Stem cell source | ||
| Peripheral blood | 51 (100) | |
| Cord blood or bone marrow | 0 (0) | |
| HLA matching | ||
| Matched related | 19 (37) | |
| Matched unrelated | 16 (31) | |
| Mismatched related | 13 (25) | |
| Mismatched unrelated | 3 (6) | |
| CMV serostatus | ||
| Donor positive/recipient positive | 51 (100) | |
| Remission before HCT | 27 (53) | |
| Acute GVHD | 13 (25) | |
| Chronic GVHD | 13 (25) | |
| Preemptive ganciclovir therapy | 17 (33) | |
| Corticosteroid use before HCT | 11 (22) | |
| Corticosteroid use after HCT | 46 (90) | |
| GVHD prophylaxis regimen | ||
| Cyclosporine | 51 (100) | |
| Methotrexate | 43 (84) | |
| Tacrolimus or mycophenolate | 7 (14) | |
| CMV infection | 26 (51) | |
| Relapsing CMV infection | 10 (20) | |
| CMV disease | 3 (6) | |
Values are number (%) unless otherwise indicated. HLA, human leukocyte antigen.